Perrigo Prepares To Pioneer US OTC Birth Control Sales As ‘Supply Chain Reinvention’ Continues
Executive Summary
Firm reports Q2 net sales up 6.4% to $1.2bn while organic measure was 0.8% growth after a 2.7 percentage point drag from SKU prioritization moves. Investment planned over second half to prepare for launch of Opill sales.
You may also be interested in...
OTC Brands In Hand, Perrigo Prepares To Pump More Revenue From Private Label Portfolio
“I think that is a value creating opportunity for us as well. We have incredible consumer reach in the US,” says CEO Patrick Lockwood-Taylor. Few companies can say, in “certain categories 80% of the units sold come from us.”
First OTC Birth Control Pill Approved In US Will Launch With Three-Year Market Exclusivity
FDA approval of Perrigo subsidiary HRA’s application comes 60 years after Rx birth control was approved in the US, one year after the application was submitted, and 13 months after the Supreme Court’s Dobbs ruling. Perrigo plans to launch sales in 2024 first quarter.
Perrigo’s Next CEO Has Long OTC Brands History
Patrick Lockwood-Taylor starts as president/CEO on 30 June, succeeding Murray Kessler as Perrigo awaits FDA decision on subsidiary HRA’s proposal for first US OTC sales of daily oral contraceptive. He’s moving from president of Bayer AG’s US business and regional president, consumer health North America.